A Case of Conversion Surgery after Atezolizumab Plus Bevacizumab Treatment for Multiple Hepatocellular Carcinomas with Bile Duct Invasion-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Case of Conversion Surgery after Atezolizumab Plus Bevacizumab Treatment for Multiple Hepatocellular Carcinomas with Bile Duct Invasion

Published:2023 Issue:9 Volume:84 Page:1491-1497
ISSN:1345-2843
Container-title:Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
language:en
Short-container-title:Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc)

Author:

TOYONAKA Ryosuke¹,ARAMAKI Osamu¹,YOSHIDA Naoki¹,MURAI Kaiki¹,OHNI Sumie²,OKUBO Hironao³,YAMASHITA Hiroharu¹,OKAMURA Yukiyasu¹

Affiliation:

1. Division of Digestive Surgery, Department of Surgery, Nihon University School of Medicine

2. Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine

3. Department of Gastroenterology, Juntendo University Nerima Hospital

Publisher

Japan Surgical Association

Link

https://www.jstage.jst.go.jp/article/jjsa/84/9/84_1491/_pdf

Reference23 articles.

1. 1) Giannini EG, Farinati F, Ciccarese F, et al : Prognosis of untreated hepatocellular carcinoma. Hepatology 2015 ; 61 : 184-190

2. 2) Finn RS, Qin S, Ikeda M, et al : Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020 ; 382 : 1894-1905

3. 3) 山口和也，吉田和弘，棚橋利行他:進行消化器癌のconversion surgery．外科　2018;80:1-6

4. 4) Wang Y, Lu LC, Guan Y, et al : Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance. Exp Hematol Oncol 2021 ; 10 : 45

5. 5) Hoshino T, Naganuma A, Furusawa A, et al : A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment. Clin J Gastroenterol 2022 ; 15 : 776-783

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3